Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Davide Deodato is active.

Publication


Featured researches published by Davide Deodato.


Bioorganic & Medicinal Chemistry Letters | 2013

Discovery and synthesis of novel benzofurazan derivatives as inhibitors of influenza A virus.

Ulrich Kessler; Daniele Castagnolo; Mafalda Pagano; Davide Deodato; Martina Bernardini; Beatrice Pilger; Charlene Ranadheera; Maurizio Botta

The identification of a novel hit compound inhibitor of the protein-protein interaction between the influenza RNA-polymerase PA and PB1 subunits has been accomplished by means of high-throughput screening. A small family of structurally related molecules has been synthesized and biologically evaluated with most of the compounds showing micromolar potency of inhibition against viral replication.


Bioorganic & Medicinal Chemistry Letters | 2014

Discovery of the first potent and selective Mycobacterium tuberculosis Zmp1 inhibitor.

Mattia Mori; Francesca Moraca; Davide Deodato; Davide M. Ferraris; Petra Selchow; Peter Sander; Menico Rizzi; Maurizio Botta

The Mycobacterium tuberculosis extracellular zinc metalloprotease 1 (Zmp1) has been proposed to play a key role in phagosome maturation and to enhance the survival of Mycobacterium tuberculosis in the host. Consequently, small molecule inhibitors of Zmp1 are of pivotal importance as a tool to better understand the pathogenicity of Zmp1 and as lead candidates for pharmacological intervention. Here we combined in silico structure-based inhibitor design with biochemical studies to discover and characterize the first potent competitive Zmp1 inhibitor showing a Ki of 94 nM and a high selectivity for Zmp1 with respect to human Neprilysin.


Journal of Medicinal Chemistry | 2016

4,6-Diphenylpyridines as Promising Novel Anti-Influenza Agents Targeting the PA–PB1 Protein–Protein Interaction: Structure–Activity Relationships Exploration with the Aid of Molecular Modeling

Iuni Margaret Laura Trist; Giulio Nannetti; Cristina Tintori; Anna Lucia Fallacara; Davide Deodato; Beatrice Mercorelli; Giorgio Palù; Maikel Wijtmans; Tzveta Gospodova; Ewald Edink; Mark H.P. Verheij; Iwan J. P. de Esch; Lilia Viteva; Arianna Loregian; Maurizio Botta

Influenza is an infectious disease that represents an important public health burden, with high impact on the global morbidity, mortality, and economy. The poor protection and the need of annual updating of the anti-influenza vaccine, added to the rapid emergence of viral strains resistant to current therapy make the need for antiviral drugs with novel mechanisms of action compelling. In this regard, the viral RNA polymerase is an attractive target that allows the design of selective compounds with reduced risk of resistance. In previous studies we showed that the inhibition of the polymerase acidic protein-basic protein 1 (PA-PB1) interaction is a promising strategy for the development of anti-influenza agents. Starting from the previously identified 3-cyano-4,6-diphenyl-pyridines, we chemically modified this scaffold and explored its structure-activity relationships. Noncytotoxic compounds with both the ability of disrupting the PA-PB1 interaction and antiviral activity were identified, and their mechanism of target binding was clarified with molecular modeling simulations.


ChemMedChem | 2014

The fight against the influenza A virus H1N1: Synthesis, molecular modeling, and biological evaluation of benzofurazan derivatives as viral RNA polymerase inhibitors

Mafalda Pagano; Daniele Castagnolo; Martina Bernardini; Anna Lucia Fallacara; Ilaria Laurenzana; Davide Deodato; Ulrich Kessler; Beatrice Pilger; Lilli Stergiou; Stephan Strunze; Cristina Tintori; Maurizio Botta

The influenza RNA polymerase complex, which consists of the three subunits PA, PB1, and PB2, is a promising target for the development of new antiviral drugs. A large library of benzofurazan compounds was synthesized and assayed against influenza virus A/WSN/33 (H1N1). Most of the new derivatives were found to act by inhibiting the viral RNA polymerase complex through disruption of the complex formed between subunits PA and PB1. Docking studies were also performed to elucidate the binding mode of benzofurazans within the PB1 binding site in PA and to identify amino acids involved in their mechanism of action. The predicted binding pose is fully consistent with the biological data and lays the foundation for the rational development of more effective PA–PB1 inhibitors.


Journal of Medicinal Chemistry | 2016

Biological Characterization and in Vivo Assessment of the Activity of a New Synthetic Macrocyclic Antifungal Compound

Davide Deodato; Giorgio Maccari; Filomena De Luca; Stefania Sanfilippo; Alexandru Casian; Riccardo Martini; Silvia D’Arezzo; Francesca Bugli; Brunella Posteraro; Patrick Vandeputte; Dominique Sanglard; Jean-Denis Docquier; Maurizio Sanguinetti; Paolo Visca; Maurizio Botta

We recently identified a novel family of macrocyclic amidinoureas showing potent antifungal activity against Candida spp. In this study, we demonstrate the fungicidal effect of these compounds as well as their killing activity in a dose-dependent manner. Transcriptional analysis data indicate that our molecules induce a significant change in the transcriptome involving ATP binding cassette (ABC) transporter genes. Notably, experiments against Candida albicans mutants lacking those genes showed resistance to the compound, suggesting the involvement of ABC transporters in the uptake or intracellular accumulation of the molecule. To probe the mode of action, we performed fluorescence microscopy experiments on fungal cells treated with an ad-hoc synthesized fluorescent derivative. Fluorescence microscopy images confirm the ability of the compound to cross the membrane and show a consistent accumulation within the cytoplasm. Finally, we provide data supporting the in vivo efficacy in a systemic infection murine model setup with a drug-resistant strain of C. albicans.


Bioorganic & Medicinal Chemistry Letters | 2014

Synthesis of linear and cyclic guazatine derivatives endowed with antibacterial activity

Giorgio Maccari; Stefania Sanfilippo; Filomena De Luca; Davide Deodato; Alexandru Casian; Maria Chiara Dasso Lang; Claudio Zamperini; Elena Dreassi; Gian Maria Rossolini; Jean Denis Docquier; Maurizio Botta

Antibiotic resistance has reached alarming levels in many clinically-relevant human pathogens, and there is an increasing clinical need for new antibiotics active on drug-resistant Gram-negative pathogens who rapidly evolve towards pandrug resistance phenotypes. Here, we report on two related classes of guanidinic compounds endowed with antibacterial activity. The two best compounds (9a and 13d) exhibited the most potent antibacterial activity with MIC values ranging 0.12-8 μg/ml with most tested pathogens, including both Gram-positive and Gram-negative bacteria. Interestingly, MIC values were not affected (1-8 μg/ml) when measured using recent clinical isolates with various antibiotic resistance determinants. The results reported herein identify guazatine derivatives as an interesting starting point for the optimization of a potentially novel class of antibacterial agents.


Journal of the American Chemical Society | 2017

Photochemical Activation of Tertiary Amines for Applications in Studying Cell Physiology

Naeem Asad; Davide Deodato; Xin Lan; Magnus B. Widegren; David Phillips; Lili Du; Timothy M. Dore

Representative tertiary amines were linked to the 8-cyano-7-hydroxyquinolinyl (CyHQ) photoremovable protecting group (PPG) to create photoactivatable forms suitable for use in studying cell physiology. The photoactivation of tamoxifen and 4-hydroxytamoxifen, which can be used to activate Cre recombinase and CRISPR-Cas9 gene editing, demonstrated that highly efficient release of bioactive molecules could be achieved through one- and two-photon excitation (1PE and 2PE). CyHQ-protected anilines underwent a photoaza-Claisen rearrangement instead of releasing amines. Time-resolved spectroscopic studies revealed that photorelease of the tertiary amines was extremely fast, occurring from a singlet excited state of CyHQ on the 70 ps time scale.


Bioorganic & Medicinal Chemistry Letters | 2017

Design and synthesis of a novel inhibitor of T. Viride chitinase through an in silico target fishing protocol

Giorgio Maccari; Davide Deodato; Diego Fiorucci; Francesco Orofino; Giuseppina Ivana Truglio; Carolina Pasero; Riccardo Martini; Filomena De Luca; Jean-Denis Docquier; Maurizio Botta

In the last ten years, we identified and developed a new therapeutic class of antifungal agents, the macrocyclic amidinoureas. These compounds are active against several Candida species, including clinical isolates resistant to currently available antifungal drugs. The mode of action of these molecules is still unknown. In this work, we developed an in-silico target fishing procedure to identify a possible target for this class of compounds based on shape similarity, inverse docking procedure and consensus score rank-by-rank. Chitinase enzyme emerged as possible target. To confirm this hypothesis a novel macrocyclic derivative has been produced, specifically designed to increase the inhibition of the chitinase. Biological evaluation highlights a stronger enzymatic inhibition for the new derivative, while its antifungal activity drops probably because of pharmacokinetic issues. Collectively, our data suggest that chitinase represent at least one of the main target of macrocyclic amidinoureas.


Journal of Medicinal Chemistry | 2016

Development and in Vitro Evaluation of a Microbicide Gel Formulation for a Novel Non-Nucleoside Reverse Transcriptase Inhibitor Belonging to the N-Dihydroalkyloxybenzyloxopyrimidines (N-DABOs) Family

Cristina Tintori; Annalaura Brai; Maria Chiara Dasso Lang; Davide Deodato; Antonia Michela Greco; Bruno Mattia Bizzarri; Lorena Cascone; Alexandru Casian; Claudio Zamperini; Elena Dreassi; Emmanuele Crespan; Giovanni Maga; Guido Vanham; Elisa Rita Ceresola; Filippo Canducci; Kevin K. Ariën; Maurizio Botta

Preventing HIV transmission by the use of a vaginal microbicide is a topic of considerable interest in the fight against AIDS. Both a potent anti-HIV agent and an efficient formulation are required to develop a successful microbicide. In this regard, molecules able to inhibit the HIV replication before the integration of the viral DNA into the genetic material of the host cells, such as entry inhibitors or reverse transcriptase inhibitors (RTIs), are ideal candidates for prevention purpose. Among RTIs, S- and N-dihydroalkyloxybenzyloxopyrimidines (S-DABOs and N-DABOs) are interesting compounds active at nanomolar concentration against wild type of RT and with a very interesting activity against RT mutations. Herein, novel N-DABOs were synthesized and tested as anti-HIV agents. Furthermore, their mode of binding was studied by molecular modeling. At the same time, a vaginal microbicide gel formulation was developed and tested for one of the most promising candidates.


Bioorganic & Medicinal Chemistry Letters | 2018

Design, synthesis, SAR and biological investigation of 3-(carboxymethyl)rhodanine and aminothiazole inhibitors of Mycobacterium tuberculosis Zmp1

Mattia Mori; Davide Deodato; Mohan Kasula; Davide M. Ferraris; Adriana Sanna; Alessandro De Logu; Menico Rizzi; Maurizio Botta

Sixteen 3-(carboxymethyl)rhodanines, and twelve aminothiazoles as rhodanine-mimetics were designed, synthesized and tested as inhibitors of the Zmp1 enzyme from Mycobacterium tuberculosis (Mtb). Almost all rhodanines (5a-d, 5f-n, and 7a-b) exhibited Zmp1 inhibition with IC50 values in the range 1.3-43.9 µM, whereas only aminothiazoles 12b and 12d proved active with IC50 values of 41.3 and 35.7 µM, respectively. Structure-activity relationships (SAR) were coupled with molecular modeling studies to highlight structural determinants for Zmp1 inhibition. Moreover, rhodanines 5a and 5c induced 23.4 and 53.8% of Mtb growth inhibition in THP-1 infected cells, respectively, at the non-toxic concentration of 10 µg/ml. This work represents a step forward in targeting Zmp1 by small molecules.

Collaboration


Dive into the Davide Deodato's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Brunella Posteraro

Catholic University of the Sacred Heart

View shared research outputs
Researchain Logo
Decentralizing Knowledge